Cancer antigen marker

Serum cancer antigen 125 (CA-125) is the most extensively evaluated tumor marker for ovarian cancer. Unfortunately, the CA-125 determination is non-specific, and elevated levels can be associated with a number of other gynecologic and gastrointestinal diseases. CA-125 levels in a woman without ovarian cancer, though, are static or tend to decrease over time, whereas levels associated with malignancy will continue to rise.10 Since CA-125 is a non-specific marker, there is no standard recommendation for routine screening for prevention of ovarian cancer. 

Some gangliosides of the globo series (Globo-H, sLcx hexasaccharyl ceramide, etc.) are useful cancer cell markers because they are elevated in the membranes of certain types of tumor cells such as melanomas and metastatic brain tumors. A number of GSLs play a role as tumor-associated carbohydrate antigens (TACAs)... 

Canney PA, Moore M, Wilkinson PM, James RD, Ovarian cancer antigen CA 125 a prospective clinical assessment of its role as a tumor marker, Br. J. Cancer, 50 765-769, 1984. 

Tumour markers. Specific types of cancer may produce so-called tumour markers. These markers can be monitored by serum samples that will show the amount of the marker in the blood. Again it is essential to have a baseline measurement of the specific tumour marker in order to monitor any change during treatment. In the case of Mrs KT, a baseline measurement of the CEA (carcinoembryonic antigen) marker should be taken and then monitored at each cycle of treatment. Response to treatment should be demonstrated by a progressive reduction in tumour marker levels. 

Cancer antigen 125 a glycoprotein marker nsed for prognosis in ovarian cancer also referred to as MUC16... 

B. H., Synthesis and enzyme inhibitory activities of novel peptide isosteres, Curr. Med. Chem. 9, 2243-2270, 2002 Roy, R. and Baek, M.G., Glyco-dendrimers novel glycotope isosteres unmasking sugar coding. Case study with T-antigen markers from breast cancer MUCl glycoprotein, J. Bio-technoL 90, 291-309, 2002 Rye, C.S. and Baell, J.B., Phosphate isosteres in medicinal chemistry, Curr. Med. Chem. 12, 3127-3141, 2005. 

Lamerz R. CA19-9 GICA (gastrointestinal cancer antigen). In Sell S, ed. Serological cancer markers. Totowa, NJ Humana Press, 1992 309-39. 

Chedid A, Chejfec G, Eichorst M, et al. Antigenic markers of hepatocellular carcinoma. Cancer. 1990 65 84-87. 

Horoszewicz JS, Kawinski E, Murphy GP. Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients. Anticancer Res. 1987 7 927-935. 

CA (cancer antigen) 19-9 Tumor marker TPrA, Rufbpylj (223)... 

A second sensor based on ELP was reported by Chen and co-woilcers (Gao et al., 2005). The ELP is fused to antibodies for a tumor marker (cancer antigen 19-9, CA 19-9) and subsequently used to inamobilise the antibodies to a surface. In this case, the temperature responsiveness of the ELP was used for the fabrication of the sensor detection occurred via the addition of a second, fluorescently labelled antibody to the tumor marker after the marker had been immobilised. This biosensor had a detection limit of 21 units/mL for CA 19-9. 

Cellular therapies in transplantation and cancer are based on specific cells separated or sorted from human blood, bone marrow, or cord blood by means of their specific cell surface markers or cell differentiation antigens, e.g., CD3, CD4, CD8, CD 14, CD 19, and CD34. For example, the CD34+ stem cells, especially those derived from human embryos, have the capacity to differentiate in culture to generate different somatic cells, e.g., liver cells, heart cells, neurons, etc. This exploding field of research is now termed regenerative medicine. 

Intervention trials confirmed this protective role of lycopene on prostate cancer risk. Three primary intervention studies evaluated the effect of lycopene supplementation on prostate cancer risk or on certain risk markers such as prostate-specific antigen (PSA) plasma concentration or oxidative alterations of leucocyte DNA. - All showed increases of plasma and prostate lycopene levels after diet supplementation with lycopene and inverse correlations between tumor incidence and risk biomarkers. 

Prostate-specific antigen (PSA) is a useful marker for detecting prostate cancer at early stages, predicting outcome for localized disease, defining disease-free status, and monitoring response to... 

---